BRAF and melanoma: The fact that FGF5 is present in about 60% of benign nevi and in an even higher percentage of primary melanoma, but is not further enhanced in metastatic compared to primary melanoma suggests that - similar to BRAF mutations [26] – FGF5 expression may be an early event in melanoma development and less important once metastasis has occurred.